John Jenkins, director of the Office of New Drugs, says, "There's the perception in the outside world that OND is always overruling OSE [Office of Surveillance & Epidemiology] in a way that may be viewed as less focused on safety. But there are cases where the OND perspective is more conservative on the safety issue than the feedback we're getting from our OSE colleagues."

Full Story:

Related Summaries